Assessment of biotechnological products specific activity

The review looks into various aspects of assessing specific activity of biotechnological products, which is one of their key quality parameters. Approaches to the analysis of this parameter and the choice of test procedures are governed by the nature and characteristics of a medicinal product. Test procedures should be adequate and have sufficient sensitivity and specificity. Specific activity of the products in question can be assessed by biological methods both in vivo using laboratory animals, which demonstrate the most adequate response to the tested product, and in vitro using sensitive cell lines. Assessment of specific biological activity helps to characterize the product’s pharmacological action and systematically examine the mechanisms of therapeutic effects in clinical practice. Therefore, specific activity of biotechnological products should be assessed using methods appropriate for the proposed mechanism of action. Many biotechnological products, such as cytokine system products, mAbs, fusion proteins and some others call for individual methods for assessment of their specific activity. Biotechnological products are successfully used in the treatment of autoimmune, infectious, oncological, and allergic diseases.

биотехнологические лекарственные препараты, цитокины, моноклональные антитела, специфическая биологическая активность, методы исследования в условиях in vitro и in vivo, линии клеток, biotechnological products, cytokines, monoclonal antibodies, specific biological activity, in vitro and in vivo test methods, cell lines

1. Federal Law of 12.04.2010, ¹ 61-FZ «On Circulation of Medicines» (in Russian).

2. Guidelines on the quality, safety, and efficacy of biotherapeutic protein products prepared by recombinant DNA technology. Replacement of Annex 3 of WHO Technical Report Series, No. 814. WHO. 2013.

3. Avdeeva ZhI, Volkova RA, Alpatova NA, Borisevich IV. General principles of development of preclinical studies program for immunobiological medicinal preparations produced using genetic engineering methods. Tsitokiny i vospalenie. 2011; 10(4): 5–10 (in Russian).

4. Avdeeva ZhI, Alpatova NA, Soldatov AA, Bondarev VP, Bunyatyan ND, Merkulov VA, et al. Aspects of preclinical studies of biotech drugs. Immunologiya 2015; 36(5): 306–12 (in Russian).

5. Alpatova NA, Avdeeva ZhI, Soldatov AA, Bondarev VP, Medunitsyn NV. Basis of measurement the specific activity of biotech medicinal preparations. Tsitokiny i vospalenie 2015; 14(3): 12–6 (in Russian).

6. Yakovlev AK, Gayderova LA, Alpatova NA, Lobanova TN, Postnova EL, Yurchikova EI, et al. Studying of the standardization principles of pharmacological activity of recombinant erythropoietin preparations. Standartnye obraztsy 2016; (1): 8–20 (in Russian).

7. Motuzova EV, Alpatova NA, Gayderova LA, Runova OB, Volkova RA, Mytsa ED, et al. Development and certification of an industrial reference standard for determination of filgrastim activity. Biopreparations. Prevention, Diagnosis, Treatment 2016; 16(3): 172–8 (in Russian).

8. Yarilin AA. Immunology. Moscow: GEOTAR-Media; 2010 (in Russian).

9. Ketlinskij SA, Simbircev AS. Cytokines. St. Petersburg: Foliant; 2008 (in Russian).

10. Simbirtsev AS. Cytokines — a new system of regulation of defense reactions. Tsitokiny i vospalenie. 2002; 1(1): 9–16 (in Russian).

11. Barinov AN. Pelvic pain from the position of neurologist. Available from: http://inmeda.info/images/restricted/pelvicpain.pdf (in Russian).

12. Medunitsyn NV, Avdeeva ZhI, Alpatova NA. Preparations based on cytokines for immunotherapy. In: Sb. trudov 5-go Kongressa «Sovremennye problemy allergologii, immunologii i immunofarmakologii». V. 1. Aktovye i plenarnye lektsii. Moscow. 2002. P. 381–97 (in Russian).

13. Avdeeva ZhI. Medications of cytokines. Biopreparations. Prevention, Diagnosis, Treatment 2005; (1): 17–21 (in Russian).

14. Popov VF, Popov OV. Dosage forms of interferon: Ref. Physician. Moscow: Triada-X, 2002 (in Russian).

15. Rzheshevskiy AV. The golden age of viruses. Populyarnaya mekhanika 2015; (9): 410–44 (in Russian).

16. Avdeeva ZhI, Soldatov AA, Alpatova NA, Kiselevskiy MV, Lysikova SL, Bondarev VP, et al. Recombinant granulocyte colony stimulating factor biosimilars. Quality assessment. Biopreparations. Prevention, Diagnosis, Treatment 2015; (1): 4–14 (in Russian).

17. Elliott S, Pham E, Macdougall IC. Erythropoietins: a common mechanism of action. Exp Hematol. 2008; 36(12): 1573–84.

18. Merkulov VA, Soldatov AA, Avdeeva ZhI, Alpatova NA, Gayderova LA, Yakovlev AK, Medunitsyn NV. Recombinant erythropoietin preparations and their characteristics. Biopreparations. Prevention, Diagnosis, Treatment 2013; (3): 4–11 (in Russian).

19. Shestakova MV, Martynov SA. Anemia in diabetic nephropathy: prognostic value, diagnosis and treatment. Consilium medicum 2006; 9: 39–43 (in Russian).

20. Koval’chuk LV, Gankovskaya LV, Meshkova RYa. Clinical immunology and allergology with the basics of immunology. Moscow: GEOTAR-Media; 2012 (in Russian).

21. Lyagoskin IV, Berestovoy MA, Poteryaev DA, Zeynalova ES, Vishnevskiy AYu, Kazarov AA. Validation of the XTT-test for assessing the antiproliferative activity of biologics on the basis of monoclonal antibodies. Biopreparations. Prevention, Diagnosis, Treatment 2015; (1): 45–50 (in Russian).

22. Guideline on development, production, characterization and specifications for monoclonal antibodies and related products. London: EMA. 2008.

23. Avdeeva ZhI, Alpatova NA, Volkova RA, Lapteva LK. Medicinal preparations based on monoclonal antibodies. Biopreparations. Prevention, Diagnosis, Treatment 2011; (2): 14–9 (in Russian).

24. Ivanov AA, Beletskiy IP. Monoclonal antibody therapy — panacea or palliative? Remedium 2011; (3): 12–6 (in Russian).

25. Guidelines for conducting preclinical studies of drugs (immunobiological medicines). V. II. Moscow: Grief and K; 2013 (in Russian).

26. Avdeeva ZhI, Soldatov AA, Alpatova NA, Medunitsyn NV, Bondarev VP, Mironov AN, et al. Preparations of next generation monoclonal antibodies (issues and prospects). Biopreparations. Prevention, Diagnosis, Treatment 2015; (1): 21–35 (in Russian).

27. Khaitov RM, Yarilin AA, Pinegin BV. Immunology. Atlas. Moscow: GEOTAR-Media; 2011. P. 302 (in Russian).

28. Sigidin YaA, Lukina GV. Biological therapy in rheumatology. Moscow: Practical Meditsine; 2009 (in Russian).

29. Eliseev MS, Barskova VG, Nasonov EL. Tumor necrosis factor (TNF) role in the development of metabolic disturbances and atherosclerosis and TNF antagonists influence on them in patients with rheumatic diseases. Rheumatology Science Practice 2009; 2: 67–73 (in Russian).

30. Kovalenko VN, Golovach IYu, Bortkevych OP. Current objectives for target treatment of rheumatoid arthritis: from monoclonal antibodies to blockers of signaling pathways molecules. Ukrainskiy revmatologicheskiy zhurnal 2012; 49(3): 5–14 (in Russian).

31. Tarhini AA, Iqbal F. CTLA-4 blockade: therapeutic potential in cancer treatments. Onco Targets Ther. 2010; 3: 15–25.

32. Demidov LV, Kharkevich GYu, Mikhaylova IN, Petenko IN, Samoylenko IV, Utyashev IA. New trends in the treatment of patients with melanoma. Vestnik moskovskogo onkologicheskogo obshchestva. Informatsionnyy byulleten 2011; 9(580): 4–6 (in Russian).

33. Moiseenko VM. Options of monoclonal antibodies in the treatment of malignant tumors. Ðractical oncology 2002; 3(4): 253–61 (in Russian).

34. Protsenko GA. The prospects of rituximab usage in rheumatology. Ukrainskiy revmatologicheskiy zhurnal 2009; 1(35): 44–7.

35. Cohen SB, Emery P, Greenwald MW, Dougados M, Eurie RA, Genovese MC, et al. Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks. Arthritis Rheum. 2006; 54(9): 2793–806.

36. Nasonov EL. Rituximab in the treatment of rheumatic diseases. Nauchno-prakticheskaya revmatologiya 2008. Prilozhenie k ¹ 1: 3–10 (in Russian).

37. Nasonov EL, ed. Anti-B-cell therapy in rheumatology: a focus on rituximab. Monograph. Moscow: IMA-PRESS; 2012 (in Russian).

38. Maddocks KJ, Lin TS. Update in the management of chronic lymphocytic leukemia. J Hematol Oncol. 2009; 2: 2–29.

39. Taylor RP, Lindorfe MA. Drug insight: the mechanism of action of Rituximab in autoimmune disease-the immune complex decoy hypothesis. Nat Clin Pract Rheumatol. 2007; 3(2): 86–95.

40. Miroshnika OA, ed. Immunomodulators in Russia: Spravochnik. Omsk: GP «Omskaya oblastnaya tipografiya»; 2014. V. 1 (in Russian).

41. Besova NS. Duration of therapy by Herceptin at a HER2 positive breast cancer. Effektivnaya farmakoterapiya. Onkologiya, gematologiya i radiologiya 2012; 1: 14–21 (in Russian).

42. Gan’shina IP, Zhukova LG, Tyurin IE. Pertuzumab — a new view on HER2-positive metastatic breast cancer. Farmateka 2014; (17): 52–9 (in Russian).

43. Baselga J, Gelmon KA, Verma S, Wardley A, Conte P, Miles D, et al. Phase II trial of pertuzumab and trastuzumab in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer that progressed during prior trastuzumab therapy. J Clin Oncol. 2010; 28(7): 1138–44.

44. Jones K, Buzdar AU. Evolving novel anti-HER2 strategies. Lancet Oncol. 2009; 10(12): 1179–87.

45. Korman DB. Targets and mechanisms of action of antineoplastic preparations. Moscow: Prakticheskaya meditsina 2014. P. 150 (in Russian).